Prosecution Insights
Last updated: November 18, 2026

Noile-Immune Biotech, Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Analysis

Noile-Immune Biotech, Inc. manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action currently active. This action is located within the distinct art units identified in the data, which indicates a specific technical focus for the company's current intellectual property efforts. The concentration in a single art unit suggests that the company is not currently navigating multiple different technical review sections at the USPTO.

The prosecution for this portfolio is conducted by the distinct examiners listed, including TIWARI, VYOMA SHUBHAM. This individual is the busiest examiner for the company, with a busiest examiner pending count of 1. Since the busiest examiner pending count is equal to the total number of pending office actions, the company's entire active prosecution docket is under the review of this one individual. This singular point of contact means that the company's immediate patent outcomes are tied to the specific examination patterns of TIWARI, VYOMA SHUBHAM.

With the specified examiner and art unit involved, the prosecution profile is highly focused. There are no other pending actions identified in the current data. The company's primary objective is to address its current workload within the Biotechnology & Pharmaceuticals sector. This streamlined structure allows for a dedicated response strategy tailored to the requirements of the single examiner involved.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§102 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MONTANARI, DAVID A 1 64.7% +49.2%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18554372 METHOD FOR ACTIVATING T-CELLS MONTANARI, DAVID A —

Top Art Units

Art UnitApps
1632 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18554372 METHOD FOR ACTIVATING T-CELLS MONTANARI, DAVID A 1632 §102Other Final Rejection — Pending Oct 06, 2023

Managing Noile-Immune Biotech, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Noile-Immune Biotech, Inc. have?

Noile-Immune Biotech, Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Noile-Immune Biotech, Inc. applications?

David A Montanari has the most, with 1 of Noile-Immune Biotech, Inc.'s pending office actions.

What technology area are Noile-Immune Biotech, Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month